Bioengineered hybrid fibers for regenerative medicine
The largest organ of the human body, muscle, accounts for 40% of total body mass. It is essential to maintaining life. Muscle tissue has a unique ability to regenerate spontaneously. In serious injuries, such as those caused by car accidents or tumor removals that result in volumetric muscle loss (VML), muscle recovery is severely impaired. VML treatment currently involves surgical interventions using autologous muscles flaps or grafts, accompanied by physiotherapy. Surgery can often result in reduced muscle function and, in some cases, graft failure. There is a need for more therapeutic options in order to improve the recovery of muscle lost.
Induce de novo regeneration by integrating transplanted cells is a promising strategy for improving the functional capability of damaged muscle. To treat muscle loss, different types of cells have been used, such as satellite cells (muscle cells), myoblasts and mesenchymal cells. Nevertheless, invasive muscle biopsy, poor cell availability and limited long-term preservation impede clinical translation. Millions to billions mature cells may need to be required to provide therapeutic benefit.